



## Hidradenitis Suppurativa (HS): Current and Emerging Treatments

Guest Editor:

**Dr. Claudio Marasca**

“Antonio Cardarelli” National  
Hospital of Naples, Naples, Italy

Deadline for manuscript  
submissions:

**closed (20 February 2024)**

### Message from the Guest Editor

Hidradenitis suppurativa (HS) to date remains a difficult disease for the dermatologist to manage due to gaps in knowledge about its etiology. There are few therapeutic choices for the treatment of HS. To date, the only FDA-approved drug remains Adalimumab (antiTNF $\alpha$ ).

However, recent studies on the pathogenesis of HS have made it possible to investigate new therapies. Thanks to the many clinical trials currently underway in the future, it is hoped that therapeutic choices can be expanded.

This Special Issue, entitled “Hidradenitis Suppurativa: Current and Emerging Therapies”, aims to bring together articles in which new therapies that specifically target cytokines involved in the pathogenesis of HS can be discussed. We hope that this Special Issue will expand the knowledge on this disease and invite colleagues to report their experiences.

### Keywords

- Hidradenitis Suppurativa
- treatment
- adalimumab
- secukinumab
- guselkumab
- biologic therapies
- small molecules





an Open Access Journal by MDPI

## Editors-in-Chief

**Prof. Dr. Emmanuel Andrès**

Internal Medicine Department,  
University Hospital Strasbourg,  
67000 Strasbourg, France

**Prof. Dr. Kent Doi**

Department of Emergency and  
Critical Care Medicine, University  
of Tokyo, Tokyo 113-8655, Japan

## Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Medicine, General & Internal*) / CiteScore - Q1 (*General Medicine*)

## Contact Us

*Journal of Clinical Medicine* Editorial  
Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jcm](http://mdpi.com/journal/jcm)  
[jcm@mdpi.com](mailto:jcm@mdpi.com)  
[X@JCM\\_MDPI](https://twitter.com/JCM_MDPI)